# Hemab Therapeutics (COAG) — Analyst Forecast

COAG · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/coag/forecast

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 15, 2026 | JP Morgan | Initiated Coverage | Overweight | $70.00 |
| Oct 12, 2026 | Rodman & Renshaw | Initiated Coverage | Buy | $56.00 |
| Aug 12, 2026 | Wedbush | Maintained | Outperform | $64.00 |
| Aug 11, 2026 | HC Wainwright & Co. | Maintained | Buy | $60.00 |
| Jul 13, 2026 | HC Wainwright & Co. | Maintained | Buy | $52.00 |
| Jul 13, 2026 | Wedbush | Maintained | Outperform | $55.00 |
| Jul 13, 2026 | Jefferies | Maintained | Buy | $47.00 |
| Jun 26, 2026 | HC Wainwright & Co. | Maintained | Buy | $40.00 |
| Jun 17, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $40.00 |
| May 26, 2026 | Wedbush | Initiated Coverage | Outperform | $42.00 |
| May 26, 2026 | Evercore ISI Group | Initiated Coverage | Outperform | $50.00 |
| May 26, 2026 | Goldman Sachs | Initiated Coverage | Buy | $36.00 |
| May 26, 2026 | Jefferies | Initiated Coverage | Buy | $39.00 |

## Frequently Asked Questions

### What is the latest analyst rating on COAG?

On Oct 15, 2026, JP Morgan initiated coverage of Hemab Therapeutics at Overweight with a price target of $70.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).